-
-
-
-
-
-
-
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
-
-
-
-
-
-
-
Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
-
-
-
-
-
-
-
Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update
-
-
-
-
-
-
-
Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock
-
-
-
-
-
-
-
EY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San Diego
-
-
-
-
-
-
1,180,393 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

